GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2025
0mins
Source: Businesswire
Clinical Trial Results: GenSight Biologics reported that their gene therapy LUMEVOQ (lenadogene nolparvovec) showed sustained visual acuity improvement in patients with Leber Hereditary Optic Neuropathy (LHON) five years after treatment, with bilateral injections yielding better outcomes than unilateral ones.
Safety Profile: The safety profile of LUMEVOQ remained favorable, with no serious adverse events reported and mild intraocular inflammation being the main ocular side effect, confirming its comparability between bilaterally and unilaterally treated subjects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
